Key result
SARS-CoV-2 NSP1 potently inhibits translation by binding to the open head conformation of the human 40S ribosomal subunit, dynamically competing with mRNA accommodation in the entry channel.
Why the study?
A molecular framework of how SARS-CoV-2 manipulates host cellular machinery to facilitate infection remains unclear.
Effect estimate: IC50 510 nM
SARS-CoV-2 NSP1 inhibits host translation by directly binding the human 40S ribosomal subunit and competing with mRNA for the entry channel.
Should not yet change practice; extends prior NSP1–40S structures and leaves open whether blocking this competition is a viable antiviral target.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta-CoV that recently emerged as a human pathogen and is the causative agent of the COVID-19 pandemic. A molecular framework of how the virus manipulates host cellular machinery to facilitate infection remains unclear. Here, we focus on SARS-CoV-2 NSP1, which is proposed to be a virulence factor that inhibits protein synthesis by directly binding the human ribosome. We demonstrate biochemically that NSP1 inhibits translation of model human and SARS-CoV-2 messenger RNAs (mRNAs). NSP1 specifically binds to the small (40S) ribosomal subunit, which is required for translation inhibition. Using single-molecule fluorescence assays to monitor NSP1-40S subunit binding in real time, we determine that eukaryotic translation initiation factors (eIFs) allosterically modulate the interaction of NSP1 with ribosomal preinitiation complexes in the absence of mRNA. We further elucidate that NSP1 competes with RNA segments downstream of the start codon to bind the 40S subunit and that the protein is unable to associate rapidly with 80S ribosomes assembled on an mRNA. Collectively, our findings support a model where NSP1 proteins from viruses in at least two subgenera of beta-CoVs associate with the open head conformation of the 40S subunit to inhibit an early step of translation, by preventing accommodation of mRNA within the entry channel.
No takes yet. Share an insight, caveat, or question.
Lapointe et al. (2021) studied SARS-CoV-2 translation inhibition. SARS-CoV-2 NSP1 vs. Absence of NSP1 or mutant NSP1 was evaluated on Translation inhibition of model mRNAs (IC50 510 nM). SARS-CoV-2 NSP1 potently inhibits translation by binding to the open head conformation of the human 40S ribosomal subunit, dynamically competing with mRNA accommodation in the entry channel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: